AIM is pleased to announce that it has been acquired by Blue Matter, a leading strategic consulting firm specializing in the life science industry.  AIM will continue to operate under its own name and maintain its identity as a leading specialist in life science supply chains.  The new arrangement is expected to provide strategic and mutual benefits to both AIM and Blue Matter.

AIM will provide a strategic complement to Blue Matter’s offerings and enhance its Pathfinder^SM suite of capabilities, which are designed to help biopharma companies enter European markets and succeed.  According to George Schmidt, Blue Matter Managing Partner in London, “We typically lead strategy work, but clients often have specialized needs when it comes to establishing operations in Europe, such as building and running flawless supply chains. AIM directly addresses that need.”

AIM’s founder, Richard de Bakker added, “Blue Matter and AIM have a long, positive relationship. We often serve the same clients, with needs that intersect the capabilities of both firms. By joining forces, we can boost the value of each firm while providing enhanced services to clients. It will also provide additional opportunities for AIM’s consulting team.”

Blue Matter’s proximity to emerging companies in the US will allow AIM to engage with them earlier, as they decide whether and how to enter Europe. AIM will continue providing consultancy and interim management services to pharmaceutical companies in Europe and elsewhere.

The acquisition was finalized on December 31, 2020.